Graeme M Rocker1, A Catherine Simpson2, Robert Horton3, Tasnim Sinuff4, Jillian Demmons2, Paul Hernandez5, Darcy Marciniuk6. 1. Division of Respirology, QEII Health Sciences Centre, Halifax, NS ; Division of Palliative Medicine, QEII Health Sciences Centre, Halifax, NS ; Faculty of Medicine, Dalhousie University, Halifax, NS. 2. Division of Respirology, QEII Health Sciences Centre, Halifax, NS. 3. Division of Palliative Medicine, QEII Health Sciences Centre, Halifax, NS ; Faculty of Medicine, Dalhousie University, Halifax, NS. 4. Department of Critical Care and Division of Respirology, Sunnybrook Health Sciences Centre and Sunnybrook Research Institute, Interdepartmental Division of Critical Care, University of Toronto, Toronto, Ont. 5. Division of Respirology, QEII Health Sciences Centre, Halifax, NS ; Faculty of Medicine, Dalhousie University, Halifax, NS. 6. Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine, University of Saskatchewan, Saskatoon, Sask.
Abstract
BACKGROUND: Dyspnea that is refractory to conventional treatments affects up to 50% of patients with advanced chronic obstructive pulmonary disease (COPD). Although professional societies recommend opioids in this setting, evidence supporting their use over months is limited. We conducted a multicentre mixed-methods study to understand patients' experiences when opioids are added to optimized conventional treatments for advanced COPD. METHODS: A total of 44 patients (median age 74, range 51-89 years) agreed to participate in this 6-month study. After baseline assessments, immediate-release morphine sulfate syrup (initially 0.5 mg twice daily) was slowly titrated upward based on weekly assessments of symptoms. We conducted semistructured interviews and collected contemporaneous measures of health-related quality of life, severity of dyspnea, anxiety, depression, global ratings of opioid "helpfulness" and adverse effects before, at 2 months and at 4-6 months after opioids were started. RESULTS: Of the 44 patients, 32 (73%) completed the trial; 27 (90%) of 30 patients reported the opioid treatment as very (43%) or somewhat (47%) helpful. Three main themes emerged from the patients' overall positive experiences: small gains have big impact; realign hopes with reality; and "try it." Significant improvements were observed in median (interquartile range) scores between baseline and 4-6 months' assessment for health-related quality of life (Chronic Respiratory Questionnaire: 3.5 [2.8-4.0] v. 4.2 [3.6-4.8]; and Chronic Respiratory Questionnaire-Dyspnea domain: 2.8 [2.3-3.6] v. 3.9 [2.8-4.5]) and decreases in severity of dyspnea (numerical rating scale: 7.0 [5.0-8.0] v. 5.0 [4.0-6.0]). Adverse effects were minimal for most patients. INTERPRETATION: Opioids were a helpful and acceptable intervention for refractory dyspnea in patients with advanced COPD. Many of the patients experienced sustained benefits over months, which supports recent recommendations to consider opioids in this setting. TRIAL REGISTRATION: ClinicalTrial.gov, no. NCT00982891.
BACKGROUND:Dyspnea that is refractory to conventional treatments affects up to 50% of patients with advanced chronic obstructive pulmonary disease (COPD). Although professional societies recommend opioids in this setting, evidence supporting their use over months is limited. We conducted a multicentre mixed-methods study to understand patients' experiences when opioids are added to optimized conventional treatments for advanced COPD. METHODS: A total of 44 patients (median age 74, range 51-89 years) agreed to participate in this 6-month study. After baseline assessments, immediate-release morphine sulfate syrup (initially 0.5 mg twice daily) was slowly titrated upward based on weekly assessments of symptoms. We conducted semistructured interviews and collected contemporaneous measures of health-related quality of life, severity of dyspnea, anxiety, depression, global ratings of opioid "helpfulness" and adverse effects before, at 2 months and at 4-6 months after opioids were started. RESULTS: Of the 44 patients, 32 (73%) completed the trial; 27 (90%) of 30 patients reported the opioid treatment as very (43%) or somewhat (47%) helpful. Three main themes emerged from the patients' overall positive experiences: small gains have big impact; realign hopes with reality; and "try it." Significant improvements were observed in median (interquartile range) scores between baseline and 4-6 months' assessment for health-related quality of life (Chronic Respiratory Questionnaire: 3.5 [2.8-4.0] v. 4.2 [3.6-4.8]; and Chronic Respiratory Questionnaire-Dyspnea domain: 2.8 [2.3-3.6] v. 3.9 [2.8-4.5]) and decreases in severity of dyspnea (numerical rating scale: 7.0 [5.0-8.0] v. 5.0 [4.0-6.0]). Adverse effects were minimal for most patients. INTERPRETATION: Opioids were a helpful and acceptable intervention for refractory dyspnea in patients with advanced COPD. Many of the patients experienced sustained benefits over months, which supports recent recommendations to consider opioids in this setting. TRIAL REGISTRATION: ClinicalTrial.gov, no. NCT00982891.
Authors: Nicholas T Vozoris; Xuesong Wang; Peter C Austin; Douglas S Lee; Anne L Stephenson; Denis E O'Donnell; Sudeep S Gill; Paula A Rochon Journal: Eur J Clin Pharmacol Date: 2017-06-29 Impact factor: 2.953
Authors: Nicholas T Vozoris; Xuesong Wang; Hadas D Fischer; Andrea S Gershon; Chaim M Bell; Sudeep S Gill; Denis E O'Donnell; Peter C Austin; Anne L Stephenson; Paula A Rochon Journal: Br J Clin Pharmacol Date: 2015-10-02 Impact factor: 4.335
Authors: Anand S Iyer; James Nicholas Dionne-Odom; Dina M Khateeb; Lanier O'Hare; Rodney O Tucker; Cynthia J Brown; Mark T Dransfield; Marie A Bakitas Journal: J Palliat Med Date: 2019-10-29 Impact factor: 2.947
Authors: David Currow; Gareth John Watts; Miriam Johnson; Christine F McDonald; John O Miners; Andrew A Somogyi; Linda Denehy; Nicola McCaffrey; Danny J Eckert; Philip McCloud; Sandra Louw; Lawrence Lam; Aine Greene; Belinda Fazekas; Katherine C Clark; Kwun Fong; Meera R Agar; Rohit Joshi; Sharon Kilbreath; Diana Ferreira; Magnus Ekström Journal: BMJ Open Date: 2017-07-17 Impact factor: 2.692
Authors: Anja Hayen; Vishvarani Wanigasekera; Olivia K Faull; Stewart F Campbell; Payashi S Garry; Simon J M Raby; Josephine Robertson; Ruth Webster; Richard G Wise; Mari Herigstad; Kyle T S Pattinson Journal: Neuroimage Date: 2017-01-03 Impact factor: 6.556
Authors: Basil G Bereza; Anders Troelsgaard Nielsen; Sverrir Valgardsson; Michiel E H Hemels; Thomas R Einarson Journal: Int J Chron Obstruct Pulmon Dis Date: 2015-04-08